Government Briefs

A lack of commitment from industry is proving to be the Achilles heel of proposed national efforts to explore high-temperature superconductivity. Even as a White House Science Council report by the so-called Gormory committee was urging the creation of a half-dozen industrial, academic, and governmental consortia to spur long-term research that could lead to commercial applications of the poorly understood phenomenon, two existing consortia were already having trouble attracting company funds.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A lack of commitment from industry is proving to be the Achilles heel of proposed national efforts to explore high-temperature superconductivity. Even as a White House Science Council report by the so-called Gormory committee was urging the creation of a half-dozen industrial, academic, and governmental consortia to spur long-term research that could lead to commercial applications of the poorly understood phenomenon, two existing consortia were already having trouble attracting company funds. One - a purely industrial venture - was formed just last year by the Microelectronics and Computer Technology Corp. in Austin, Tex. But by late January, most of its original 13 partners, including Kodak and DuPont, had left or were considering leaving after research yielded few potentially marketable products. The other, a new NSF-funded superconductivity center based at the University of Illinois, has not yet been able to attract corporate participation. Says director Miles Klein, "There just isn't enough ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies